Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

J Infect Dis. 1999 Jun;179(6):1569-72. doi: 10.1086/314753.


The safety, immunogenicity, and immunologic priming of 2 dosages (2 microgram or 10 microgram) of a meningococcal C oligosaccharide-CRM197 conjugate vaccine was evaluated in 114 infants vaccinated at ages 2, 3, and 4 months. Antibody persistence and response to boosting with 10 microgram of meningococcal C polysaccharide were assessed. The meningococcal conjugate vaccine produced fewer local reactions than concurrent routine immunizations. Total serogroup C-specific immunoglobulin geometric mean concentration (GMC) increased from 0.3 microgram/mL before vaccination to 13.1 microgram/mL at age 5 months. Serum bactericidal antibody (SBA) geometric mean titers (GMTs) rose from <1:4 to 1:1057 at 5 months and fell by 14 months to 1:19. Following boosting, anti-C-specific immunoglobulin GMC rose to 15.9 microgram/mL and SBA GMT to 1:495. Antibody responses in the 10-microgram dose cohort were significantly higher at 5 months (P<.01) than in the 2-microgram dose cohort but were lower after polysaccharide boosting (P=.02). This meningococcal conjugate vaccine was well tolerated and immunogenic and induced immunologic memory in infants.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacterial Capsules / immunology
  • Bacterial Capsules / therapeutic use
  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / immunology
  • Bacterial Vaccines / therapeutic use*
  • Female
  • Humans
  • Immunologic Memory
  • Infant
  • Male
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines
  • Vaccination


  • Bacterial Vaccines
  • Meningococcal Vaccines